RecruitMe Clinical Trial

A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects with Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor
A study for patients with high-risk Myelofibrosis (MF) using study drug imetelstat
Sponsor:Janssen Research & Development, LLC
Enrolling:Male and Female Patients
Age Range:Between 18 and 99 years old
IRB Number:AAAQ6800
U.S. Government ID:NCT02426086
Contact: Mark Heaney: 646-317-5199 / mlh2192@columbia.edu
Additional Study Information:

The purpose of this study is to find the dose of imetelstat that best treats myelofibrosis. (A doseis a measured amount of a drug taken at one time.) The effects of imetelstat on myelofibrosis as well as any side effects will be explored.

This study is closed
Investigator
Mark Heaney, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Mark Heaney
Email: mlh2192@columbia.edu
Phone: 646-317-5199